What policy makers need to know about COVID-19 protective immunity

• Published in: The Lancet (British edition) Vol. 395; no. 10236; pp. 1527 - 1529
• Main Authors: Altmann, Daniel M, Douek, Daniel C, Boyton, Rosemary J
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 16.05.2020; Elsevier Limited
• Subjects: Administrative Personnel; Animal models; Antibodies; Antibodies, Viral - blood; Betacoronavirus; Biomarkers; Clinical Laboratory Techniques; Comment; Coronavirus Infections - diagnosis; Coronavirus Infections - immunology; Coronavirus Infections - prevention & control; Coronaviruses; COVID-19; COVID-19 Testing; COVID-19 vaccines; Disease transmission; Herd immunity; Humans; Immune response; Immune system; Immunity; Immunity, Herd; Immunogenicity; Immunology; Infections; Interleukin 6; Iterative methods; Lymphocytes; Lymphocytes T; Mass Vaccination; Medical research; Pandemics; Pandemics - prevention & control; Pneumonia, Viral - diagnosis; Pneumonia, Viral - immunology; Pneumonia, Viral - prevention & control; Population; Safety; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Supply chains; Tumor necrosis factor; Tumors; Vaccines; Viral diseases; Viruses

The route to certainty on the degree and nature of the immunity required for protection will require evidence from formal proofs using approaches such as titrated transfers of antibodies and T lymphocytes to define protection in non-human primate models, as used, for example, in studies of Ebola vir...